The different types of cholesterol can be broken down into three categories : low-density lipoproteins LDL , high-density lipoproteins HDL , and triglycerides. LDL cholesterol is responsible for fatty buildups and blockage inside the arteries, so lower levels of this type are generally considered healthy.

HDL cholesterol transports LDL cholesterol to the liver to be flushed out of the body, meaning that higher levels of HDL cholesterol are beneficial. Finally, triglycerides, which are a type of lipid found in the blood, help the body store energy from food.

If triglyceride levels are too high , you may be at a higher risk for heart attack. Normal levels of each type of cholesterol can be measured via a simple blood test called a lipoprotein panel and may vary and depend on age and gender according to the CDC.

Blood sugar is important to monitor due to the many health complications that can arise from having chronically elevated or low glucose levels. Normal levels can depend on age, gender, and pregnancy, though factors such as activity levels, genetic disorders, sleep, stress, and diet can also contribute.

Glucose can be measured via a number of different tests , including an A1C test thought to be the most accurate indicator for diabetes risk , a fasting blood sugar test, a glucose tolerance test, and a random glucose test measured without fasting.

A continuous glucose monitoring CGM device can also help you measure your glucose at all times to track your levels over time and see how they are affected by your diet and lifestyle. These are the indicators for normal levels of blood sugar for each type of test according to the CDC :.

Most healthy, balanced diets should aim include all macronutrients which are fats, carbs, and protein. However, addition to factors like obesity and stress, excess consumption of fats and carbohydrates can be one of the biggest contributing factors to elevated cholesterol levels.

Things like saturated fats and certain types of processed meats such as bacon and hotdogs have been found to be correlated with unhealthy levels of cholesterol and should be consumed in moderation. Added sugars are another group that can have a negative impact on cholesterol levels.

When we eat too much sugar, the liver is forced to store the excess sugars as visceral fat , raising the cholesterol levels and increasing the risk of developing insulin resistance.

Reducing added sugar consumption may help lower cholesterol in the body. As we discussed earlier, the amount of certain fats and carbohydrates you consume can be one of the biggest contributing factors for high cholesterol. The American Heart Association recommends limiting saturated fats to 6 percent of daily calories and avoiding trans fats when possible.

Luckily however, there are also many foods that contain cholesterol-lowering properties that can make up part of a healthy balanced diet.

The benefits of exercise and physical activity go far beyond aesthetics, lowering the risk of premature death and reducing the risk of cardiovascular disease. In addition to all this, exercise can also be an effective way of lowering your cholesterol levels.

Obesity has been found to increase the amount of LDL cholesterol in the blood, and can lead to serious heart issues resulting from the accumulation of too many LDL molecules in one place. However, when we exercise, our body produces enzymes that transport the LDL molecules from the blood to the liver to be excreted.

In simple terms, the more you exercise, the more LDL your body expels. Physical activity levels can also positively impact levels of lipoproteins like HDL-C and reduce triglyceride in the blood.

High triglycerides and obesity can be risk factors for metabolic syndrome , so implementing healthy lifestyle habits such as exercising can support better overall health.

Reducing your intake of things such as added sugars can help regulate your blood glucose as well as help with weight loss, which is positively associated with cholesterol management. Adding fiber into your diet has also been proven to help prevent blood glucose fluctuations and also may help lower cholesterol levels.

Glucose and cholesterol are both important indicators for metabolic health , meaning that taking steps to manage both may help you prevent some chronic diseases. An accredited nutritionist can help guide you step by step on how to monitor your glucose levels and reduce your intake of certain foods that may be negatively impacting your cholesterol values.

Your blood sugar levels can significantly impact how your body feels and functions. When you join the Nutrisense CGM program , our team of credentialed dietitians and nutritionists are available for additional support and guidance to help you reach your goals.

Ready to take the first step? Start with our quiz to see how Nutrisense can support your health. Amanda is a Nutrition Manager and Registered Dietitian at Nutrisense, with a Masters in Dietetics from Stephen F.

Austin State University. Originally from south GA, she got her undergrad degree from Texas Tech University. Before joining Nutrisense, she worked at a hospital in Fort Worth, TX, for 4 years as a dietitian, counseling those living with HIV.

How It Works Nutritionists Journal. What Is A CGM? Get Started. natural peanut butter to the apple at breakfast, add 1 plum to A. snack and add 1 serving Guacamole Chopped Salad to dinner. Daily Totals: 1, calories, 83g protein, 75g fat, 12g saturated fat, g carbohydrate, 36g fiber, 1,mg sodium.

To make it 1, calories: Omit walnuts at A. snack and omit guacamole at dinner. To make it 2, calories: Add 1 serving Strawberry-Pineapple Smoothie to breakfast and add 2 Tbsp. natural peanut butter to P. Daily Totals: 1, calories, 82g protein, 86g fat, 12g saturated fat, g carbohydrate, 29g fiber, 1,mg sodium.

snack to 1 plum and omit yogurt and chopped walnuts at P. To make it 2, calories: Add 1 cup low-fat plain kefir to breakfast, add 1 large pear to A. Daily Totals: 1, calories, 87g protein, 78g fat, 13g saturated fat, g carbohydrate, 30g fiber, 1,mg sodium.

snack to 1 plum. To make it 2, calories: Add 1 serving Strawberry-Pineapple Smoothie to breakfast and add 30 unsalted dry-roasted almonds to P.

Meal-Prep Tip: Reserve two servings of Chicken Caesar Pasta Salad to have for lunch on Days 6 and 7. Daily Totals: 1, calories, 84g protein, 81g fat, 12g saturated fat, g carbohydrate, 31g fiber, 1,mg sodium.

To make it 1, calories: Omit almonds at P. snack and omit Basic Green Salad with Vinaigrette at dinner. To make it 2, calories: Add 15 dried walnut halves to A.

snack and add 1 avocado, sliced, to the salad at dinner. Daily Totals: 1, calories, g protein, 63g fat, 13g saturated fat, g carbohydrate, 29g fiber, 1,mg sodium.

To make it 2, calories: Add 1 serving Strawberry-Pineapple Smoothie to breakfast and add 18 dried walnut halves to A. Daily Totals: 1, calories, 73g protein, 77g fat, 13g saturated fat, g carbohydrate, 31g fiber, 1,mg sodium.

Use limited data to select advertising. Create profiles for personalised advertising. Use profiles to select personalised advertising. Create profiles to personalise content.

Use profiles to select personalised content. Measure advertising performance. Measure content performance. Understand audiences through statistics or combinations of data from different sources. Develop and improve services. Use limited data to select content. List of Partners vendors.

Meal Plans Meal Plans for Diabetes. By Emily Lachtrupp is a registered dietitian experienced in nutritional counseling, recipe analysis and meal plans. Emily Lachtrupp, M. EatingWell's Editorial Guidelines.

Reviewed by Dietitian Victoria Seaver, M. Victoria Seaver is a registered dietitian and Associate Editorial Director for EatingWell. She completed her undergraduate degree in nutrition, dietetics and food science and her masters degree and dietetic internship at the University of Vermont.

Victoria has been a part of the EatingWell. com team since In This Article View All. In This Article. Managing Diabetes and Cholesterol. Diabetes-Friendly Foods. Meal Prep.

Older research indicates that diabetic dyslipidemia has links with lower levels of high-density lipoprotein HDL cholesterol and elevated levels of low-density lipoprotein LDL cholesterol, as well as triglycerides.

As a result, individuals are at a higher risk of cardiovascular disease or stroke. According to a recent study , people with diabetes can remain at an elevated risk of heart disease even with well-controlled blood glucose levels. The researchers also state that a person can improve their coronary health by reducing their cholesterol levels.

According to the AHA , anyone over the age of 20 years should get a cholesterol test every 4—6 years. People at higher risk, such as those who have had a heart attack , should get checked more frequently. The National Library of Medicine NLM suggest the following cholesterol levels are healthy for adults:.

Recommendations state that people over the age of 20 years get their cholesterol levels checked at least every 4—6 years. Those with increased risk factors for heart disease, such as diabetes, may wish to speak with their doctor about checking their cholesterol more frequently.

A clinician can then analyze the blood and send the results to the person or their doctor, who can explain the findings and discuss any required strategies to manage levels.

If interventions, such as changes to diet or exercise, do not improve cholesterol levels, a doctor may recommend a person take cholesterol-lowering medication. To achieve this, health experts generally recommend consuming a diet rich in whole foods and fiber, such as fruits, nuts, vegetables, seeds, and whole grains.

Some suggestions include:. The Centers for Disease Control and Prevention CDC add that a person can also eat more:. A person living with diabetes who is trying to control their cholesterol should avoid certain types of food , including those with added salt or sugar.

They should also avoid foods high in cholesterol and saturated fat. The NLM also suggest avoiding foods that come from animal sources because they are often higher in saturated fat and cholesterol. They recommend consuming no more than mg of cholesterol per day in the diet.

The American Diabetes Association recommend that people with diabetes exercise most days of the week. This could involve a brisk, minute walk, 5 days per week. The CDC recommend similar exercise goals.

They indicate a person should engage in at least some physical activity every day, such as taking the stairs at work instead of an elevator. They also recommend a person perform 2 hours and 30 minutes of moderate exercise each week. To reduce the likelihood of heart disease, the National Institute of Diabetes and Digestive and Kidney Diseases recommend that people quit smoking and monitor their blood sugar, cholesterol, and blood pressure levels.

The CDC agree with this advice, recommending that males have no more than 2 alcoholic drinks per day while females should have no more than 1.

With this in mind, people may wish to consider eating foods high in fiber and low in processed sugar, salt, and saturated fat. They should also exercise regularly to help reduce their cholesterol levels. Eating a healthy diet is one way to keep cholesterol levels in check.

Learn which foods to avoid and which to prioritize to maintain healthy…. Eating healthy can help people with diabetes manage their symptoms and prevent complications. Learn more about which foods to eat and which to avoid.

It is possible for a person to have high cholesterol but low blood pressure. This can occur for various reasons. Learn more here. My podcast changed me Can 'biological race' explain disparities in health?

Why Parkinson's research is zooming in on the gut Tools General Health Drugs A-Z Health Hubs Health Tools Find a Doctor BMI Calculators and Charts Blood Pressure Chart: Ranges and Guide Breast Cancer: Self-Examination Guide Sleep Calculator Quizzes RA Myths vs Facts Type 2 Diabetes: Managing Blood Sugar Ankylosing Spondylitis Pain: Fact or Fiction Connect About Medical News Today Who We Are Our Editorial Process Content Integrity Conscious Language Newsletters Sign Up Follow Us.

In a meta-analysis of five short-term trials 16 to 26 weeks in patients with type 2 diabetes inadequately treated with oral agents or insulin, the addition of colesevelam compared with placebo modestly reduced A1C levels mean difference 0.

The meta-analysis was limited by the high or unclear risk of bias in the individual trials. Side effects can include constipation, nausea, and dyspepsia. In contrast to its effects on LDL cholesterol, colesevelam increases triglyceride concentrations by approximately 20 percent [ 66,67 ].

The clinical implications of this increase are unknown. See "Lipoprotein classification, metabolism, and role in atherosclerosis", section on 'Apolipoprotein C-III'.

Given the modest glucose-lowering effectiveness, expense, and limited clinical experience, we typically do not recommend colesevelam to improve glycemic management in patients with type 2 diabetes.

See "Management of hyperprolactinemia", section on 'Overview of dopamine agonists'. A quick-release formulation of bromocriptine has been approved by the FDA for the treatment of type 2 diabetes mellitus [ 68 ].

In short-term clinical trials in patients with type 2 diabetes mellitus, bromocriptine up to 4. Common side effects include nausea, vomiting, dizziness, and headache [ 70 ]. The mechanism of action in reducing blood sugar is unknown. Given its modest glucose-lowering effect, very frequent GI side effects, and the availability of more effective drugs, we do not recommend bromocriptine for the treatment of type 2 diabetes.

BARIATRIC METABOLIC SURGERY — In patients with type 2 diabetes and obesity, bariatric and metabolic surgical procedures that result in sustained, major weight loss have been shown to lead to at least temporary remission of diabetes in a substantial fraction of patients.

Bariatric surgical procedures are targeted at weight loss in the setting of obesity; the term "metabolic surgery" is used when a major goal of surgery is to improve diabetes or other metabolic diseases eg, nonalcoholic fatty liver disease.

Patient selection — Surgical treatment of obesity is an option to treat type 2 diabetes in appropriate surgical candidates with [ 71 ]:.

Surgical treatment has also been endorsed in patients with type 2 diabetes with BMI 30 to Given the increasing availability of potent GLPbased therapies and lack of comparative effectiveness data for bariatric surgery and these potent agents, we review these options with our patients and engage in shared decision-making.

See "Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Diabetes education' and "Bariatric surgery for management of obesity: Indications and preoperative preparation", section on 'Indications'.

Outcomes — Unblinded trials have compared bariatric surgery with medical therapy for the treatment of type 2 diabetes see "Outcomes of bariatric surgery", section on 'Diabetes mellitus'.

However, relapse of diabetes usually occurs over time, with 35 to 50 percent of patients who initially achieved diabetes remission after surgery experiencing a recurrence [ 72,75 ].

Nevertheless, bariatric surgery improves glycemia substantially and significantly more than medication therapy, and most patients have marked improvement in glycemic management for at least 5 to 15 years after surgery. The effects of bariatric surgery on diabetes-related complications are reviewed in detail elsewhere.

See "Outcomes of bariatric surgery", section on 'Diabetic complications'. Risks and concerns — Despite these impressive metabolic results, concerns remain about acute postoperative complications including the need for reoperations and rehospitalizations and rare, but potentially severe, adverse events; the long-term success rates in maintaining weight loss [ 71,80,81 ]; and the reproducibility of the results in patients with an extensive history of diabetes or with different surgical teams [ 82 ].

Some weight regain is typical within two to three years of bariatric procedures, and different procedures result in different levels of weight loss and corresponding reductions in glycemia.

Bariatric surgical procedures are reviewed in detail elsewhere. See "Bariatric procedures for the management of severe obesity: Descriptions" and "Bariatric surgery for management of obesity: Indications and preoperative preparation" and "Bariatric operations: Early fewer than 30 days morbidity and mortality".

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. See "Society guideline links: Diabetes mellitus in adults" and "Society guideline links: Diabetes mellitus in children" and "Society guideline links: Diabetic kidney disease".

These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10 th to 12 th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword s of interest.

This decision is based on glycated hemoglobin A1C assay results calculator 1 typically performed every three to six months after initial therapy. After a successful initial response to lifestyle intervention and oral therapy, the majority of patients do not maintain target A1C levels during the subsequent three to five years.

See 'Indications for a second agent' above. Options include glucagon-like peptide 1 GLP-1 receptor agonists, a dual-acting GLP-1 and glucose-dependent insulinotropic polypeptide GIP receptor agonist tirzepatide , sodium-glucose co-transporter 2 SGLT2 inhibitors, short-acting sulfonylureas eg, glipizide , glimepiride , repaglinide if sulfonylurea not chosen as initial therapy , insulin, dipeptidyl peptidase 4 DPP-4 inhibitors, and pioglitazone figure 1 and table 2.

For patients with persistent hyperglycemia while taking a maximally tolerated dose of metformin, the choice of a second medication should be individualized based on efficacy, risk for hypoglycemia, the patient's comorbid conditions, impact on weight, side effects, and cost.

These agents have been shown to have the best glycemic efficacy algorithm 1. Gastrointestinal GI side effects, contraindications, and cost may limit their use. To select a medication, we use shared decision-making with a focus on beneficial and adverse effects within the context of the degree of hyperglycemia as well as a patient's comorbidities and preferences algorithm 2.

See 'Established cardiovascular or kidney disease' above. The majority of patients in the cardiovascular and renal outcomes trials had established cardiovascular disease CVD or diabetic kidney disease DKD with severely increased albuminuria, and therefore, these are the primary indications for one of these drugs.

Patients at high CVD risk but without a prior event might benefit, but the data are less supportive. Similarly, patients without severely increased albuminuria have some benefit, but the absolute benefits are greater among those with severely increased albuminuria.

The choice of an alternative glucose-lowering medication is guided by efficacy, patient comorbidities, preferences, side effects, and cost. algorithm 2. See 'Dual agent failure' above. For most patients who do not achieve target A1C with initial dual therapy, we suggest starting insulin or a GLP-1 receptor agonist Grade 2B if neither already chosen as a second agent.

In patients on sulfonylureas and metformin who are starting insulin therapy, sulfonylureas are generally tapered and discontinued, while metformin is continued.

In patients on DPP-4 inhibitors who are starting a GLP-1 receptor agonist or dual-acting GLP-1 and GIP receptor agonist, the DPP-4 inhibitor is discontinued, while metformin is continued. See 'Dual agent failure' above and 'Insulin initiation and intensification' above. Related Pathway s : Diabetes: Initial therapy for non-pregnant adults with type 2 DM.

An alternative is two oral agents and a GLP-1 receptor agonist or dual-acting GLP-1 and GIP receptor agonist, particularly for patients in whom weight loss or avoidance of hypoglycemia is a primary consideration.

These GLPbased therapies should not be combined with DPP-4 inhibitors. Another option for patients close to glycemic goals is three oral agents eg, metformin , sulfonylurea plus: DPP-4 inhibitor, SGLT2 inhibitor, or pioglitazone.

Although guidelines suggest combining SGLT2 inhibitors and GLP-1 receptor agonists, we do not usually add an SGLT2 inhibitor to GLP-1 receptor agonist therapy for management of hyperglycemia alone, given the absence of data showing additive cardiovascular and kidney benefit and increased patient burden cost, polypharmacy, adverse effects.

Bariatric surgery may also be an option in patients with lower BMI 30 to Patients seeking bariatric surgery should be counseled to develop coping skills, eliminate maladaptive behavior, and understand the risks and benefits of the surgery. See 'Bariatric metabolic surgery' above and "Bariatric surgery for management of obesity: Indications and preoperative preparation", section on 'Preoperative counseling'.

Why UpToDate? Product Editorial Subscription Options Subscribe Sign in. Learn how UpToDate can help you. Select the option that best describes you.

View Topic. Font Size Small Normal Large. Management of persistent hyperglycemia in type 2 diabetes mellitus. Formulary drug information for this topic. No drug references linked in this topic.

Find in topic Formulary Print Share. View in. Language Chinese English. Author: Deborah J Wexler, MD, MSc Section Editor: David M Nathan, MD Deputy Editor: Katya Rubinow, MD Contributor Disclosures. All topics are updated as new evidence becomes available and our peer review process is complete.

Literature review current through: Jan This topic last updated: Jan 11, Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes Diabetes Care ; S Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, A consensus report by the American Diabetes Association ADA and the European Association for the Study of Diabetes EASD.

Diabetologia ; Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care ; Wei N, Zheng H, Nathan DM. Empirically establishing blood glucose targets to achieve HbA1c goals.

American Diabetes Association Professional Practice Committee. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS UK Prospective Diabetes Study UKPDS Group.

Lancet ; United Kingdom Prospective Diabetes Study UKPDS. BMJ ; prospective diabetes study Overview of 6 years' therapy of type II diabetes: a progressive disease. Prospective Diabetes Study Group. Diabetes ; Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies UKPDS JAMA ; GRADE Study Research Group, Nathan DM, Lachin JM, et al.

Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med ; Bressler P, DeFronzo RA. Drugs and diabetes. Diabetes Reviews ; Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes.

Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?

Ziemer DC, Doyle JP, Barnes CS, et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes IPCAAD 8. Arch Intern Med ; Grant RW, Buse JB, Meigs JB, University HealthSystem Consortium UHC Diabetes Benchmarking Project Team.

Quality of diabetes care in U. academic medical centers: low rates of medical regimen change. Fanning EL, Selwyn BJ, Larme AC, DeFronzo RA. Improving efficacy of diabetes management using treatment algorithms in a mainly Hispanic population. Grant RW, Cagliero E, Sullivan CM, et al.

A controlled trial of population management: diabetes mellitus: putting evidence into practice DM-PEP. Das SR, Everett BM, Birtcher KK, et al.

J Am Coll Cardiol ; Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Ann Intern Med ; Maruthur NM, Tseng E, Hutfless S, et al.

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Palmer SC, Mavridis D, Nicolucci A, et al.

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.

Rodbard HW, Rosenstock J, Canani LH, et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes SUSTAIN 8 : a double-blind, phase 3b, randomised controlled trial.

Lancet Diabetes Endocrinol ; Henry RR, Gumbiner B, Ditzler T, et al. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Hemmingsen B, Christensen LL, Wetterslev J, et al.

Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ ; e Yki-Järvinen H, Ryysy L, Nikkilä K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus.

A randomized, controlled trial. Wulffelé MG, Kooy A, Lehert P, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes UKPDS Russell-Jones D, Vaag A, Schmitz O, et al. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes DURATION-3 : an open-label randomised trial.

Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev ; :CD Singh S, Wright EE Jr, Kwan AY, et al.

Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab ; Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

Curovic VR, Jongs N, Kroonen MYAM, et al. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial. Shields BM, Dennis JM, Angwin CD, et al.

Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study. Nat Med ; Zheng SL, Roddick AJ, Aghar-Jaffar R, et al.

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.

Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes.

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes REWIND : a double-blind, randomised placebo-controlled trial. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 SGLT-2 inhibitors and glucagon-like peptide-1 GLP-1 receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

BMJ ; m Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

Cochrane Database Syst Rev ; CD Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease.

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Zinman B, Wanner C, Lachin JM, et al.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Patorno E, Htoo PT, Glynn RJ, et al. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.

Colling C, Atlas SJ, Wexler DJ. Application of American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.

Wexler DJ, de Boer IH, Ghosh A, et al. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. JAMA Intern Med ; Hirst JA, Farmer AJ, Dyar A, et al.

Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Nauck MA, Kahle M, Baranov O, et al. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.

Zaccardi F, Dhalwani NN, Dales J, et al. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. Davies MJ, D'Alessio DA, Fradkin J, et al.

Management of Hyperglycemia in Type 2 Diabetes, A Consensus Report by the American Diabetes Association ADA and the European Association for the Study of Diabetes EASD. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus.

A multicenter controlled clinical trial. Johnston PS, Feig PU, Coniff RF, et al. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. In Brief: A new indication for colesevelam. Med Lett Drugs Ther ; Ooi CP, Loke SC.

Colesevelam for type 2 diabetes mellitus. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Goldberg RB, Fonseca VA, Truitt KE, Jones MR.

Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Bromocriptine Cycloset for type 2 diabetes.

Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes.